Clinical Trial Update: Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of LY-3884963 for Frontotemporal dementia due to progranulin mutations is active but not recruiting, with Prevail Therapeutics listed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Frontotemporal Dementia

Drugs mentioned

• LY-3884963

Snippet

Sponsor: Prevail Therapeutics | Conditions: Frontotemporal Dementia | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING